Skip to main content

SB 778 — Maryland

Clinical Research Pharmacies and Clinical Trials - Permits and Ownership

Signed into law 2026 session Senate

This page lists STATE bills only. Open States, our source for this data, tracks state legislatures -- it has no visibility into city councils, county commissions or school boards. We don't yet have a free, storable source for local measures; see the About page for why.

Summary

  • SB 778 is a bill in the Maryland Senate, 2026 session, introduced February 6, 2026.
  • Sponsored by Feldman.
  • Current status: signed into law.
  • Most recent action (April 28, 2026): Approved by the Governor - Chapter 206.
  • 2 recorded votes; the most recent, on March 31, 2026, passed 129-6.
  • Subjects: Applicants and Applications, Classifications and Designations, Committees and Commissions, Complaints, Drugs, Ethics.

Contact your legislator about this bill

Bill text & documents

Sponsors

Primary: Feldman

History

  1. Introduced, completed
  2. Passed Senate, completed
  3. Passed House of Delegates, completed
  4. Sent to Governor, completed
  5. Signed into law, completed, current stage
  1. Senate First Reading Finance
  2. Senate Hearing 3/03 at 1:00 p.m.
  3. Senate On Third Reading

    42 yes 0 no, 5 other Passed, 100% yes

  4. Senate Favorable with Amendments Report by Finance
  5. Senate Favorable with Amendments {
  6. Senate Second Reading Passed with Amendments
  7. Senate Third Reading Passed Milestone
  8. House of Delegates Referred Health
  9. House of Delegates Hearing 4/02 at 1:00 p.m.
  10. House of Delegates On Third Reading

    129 yes 6 no, 6 other Passed, 96% yes

  11. House of Delegates Favorable Report by Health
  12. House of Delegates Favorable Adopted Second Reading Passed
  13. House of Delegates Third Reading Passed Milestone
  14. Senate Returned Passed
  15. Governor Approved by the Governor - Chapter 206 Milestone Latest

Source: Open States. Last checked November 11, 2026. How we keep this accurate ›